{"id":863527,"date":"2025-06-25T07:06:00","date_gmt":"2025-06-25T11:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/"},"modified":"2025-06-25T07:06:00","modified_gmt":"2025-06-25T11:06:00","slug":"portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/","title":{"rendered":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">DOVER, Del., June  25, 2025  (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (\u201cPortage\u201d), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.<\/p>\n<p align=\"justify\">\n        <strong>About Portage Biotech<\/strong><br \/>\n        <br \/>Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system\u2019s ability to fight cancer. For more information, visit <strong>www.portagebiotech.com<\/strong>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company\u2019s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words \u201cbelieve,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201ccontinues,\u201d or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company\u2019s ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in \u201cItem 3 &#8211; Key Information-Risk Factors\u201d in the Company\u2019s Annual Report on Form 20-F for the year ended March 31, 2024 and \u201cBusiness Environment \u2013 Risk Factors\u201d in the Company\u2019s Management\u2019s Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company\u2019s Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.<\/p>\n<p>\n        <strong>For More Information:<\/strong><br \/>\n        <br \/>Portage Biotech<br \/>Alexander Pickett, Chief Executive Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cAWWYGOUK9RNKF06lTKtnzY-ubIYLwLUBgErpuBzI-MURbwLm_8jr2wOhBm_1lU_ZZsf2PfUmz9_H8TfYSEoGF_OFmEjMj2z461P56GZNlk=\" rel=\"nofollow\" target=\"_blank\">ir@portagebiotech.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGM5ZDcyNzItNDEzOC00ZDkxLTg3MjctN2RhNTRjOWExYjAzLTEyMjEzMjItMjAyNS0wNi0yNS1lbg==\/tiny\/Portage-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (\u201cPortage\u201d), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage Biotech Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system\u2019s ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looking Statements All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company\u2019s business strategy, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-863527","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (\u201cPortage\u201d), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage Biotech Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system\u2019s ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looking Statements All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company\u2019s business strategy, &hellip; Continue reading &quot;Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-25T11:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements\",\"datePublished\":\"2025-06-25T11:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/\",\"name\":\"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\",\"datePublished\":\"2025-06-25T11:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/","og_locale":"en_US","og_type":"article","og_title":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk","og_description":"DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) &#8212; Portage Biotech Inc. (\u201cPortage\u201d or the \u201cCompany\u201d) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (\u201cPortage\u201d), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage Biotech Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system\u2019s ability to fight cancer. For more information, visit www.portagebiotech.com. Forward-Looking Statements All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company\u2019s business strategy, &hellip; Continue reading \"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-25T11:06:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements","datePublished":"2025-06-25T11:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/","name":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=","datePublished":"2025-06-25T11:06:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4Mzk4MSM3MDE2NjAwIzIyMDk3Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/portage-biotech-regains-full-compliance-with-nasdaq-continued-listing-requirements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=863527"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=863527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=863527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=863527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}